What risk factors should be considered when determining the need for OAC in AF patients undergoing PCI/stenting?
When determining the need for oral anticoagulants (OAC) in AF patients presenting with an acute coronary syndrome (ACS) and/or undergoing PCI/stenting, risk factors such as stroke (assessed using the CHA2DS2-VASc score) and bleeding risk (assessed using the HAS-BLED score) should be considered. If the HAS-BLED score is low (0-2), triple therapy (OAC + dual antiplatelet therapy) for one month may be suggested, followed by dual therapy (OAC + single antiplatelet, preferably clopidogrel) for up to 12 months, after which OAC monotherapy can be used.